CINCINNATI, OH – June 12, 2019 – Callitas Health Inc. ("Callitas" or the "Company") (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) provides its third bi-weekly Default Status Report under National Policy 12-203 Management Cease Trade Orders("NP 12-203"), pursuant to which Callitas issued its original default announcement indicating that the filing of its annual audited financial statements, [...]
CINCINNATI, OH – May 29, 2019 – Callitas Health Inc. ("Callitas" or the "Company") (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) provides its second bi-weekly Default Status Report under National Policy 12-203 Management Cease Trade Orders("NP 12-203"), pursuant to which Callitas issued its original default announcement indicating that the filing of its annual audited financial [...]
CINCINNATI, OH, May 28, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that Brian D. Keane will join the team as the Company’s Capital Markets and Merger and Acquisitions Consultant. The addition [...]
CINCINNATI, OH, May 22, 2019– Callitas Health Inc.(CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced it has completed its recently announced non-brokered private placement. The Company issued 3,856,333 units at a price of $0.075 per unit, for gross proceeds of [...]
CINCINNATI, OH – May 15, 2019 – Callitas Health Inc. ("Callitas" or the "Company") (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) announces that further to its news release dated May 1, 2019, the Company’s principal regulator, the British Columbia Securities Commission (the "BCSC") granted a management cease trade order (the "MCTO") on May 1, 2019, [...]
CINCINNATI, OH – May 1, 2019 – Callitas Health Inc. ("Callitas" or the "Company") (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) today announced that the filing of its audited annual financial statements, management's discussion and analysis and related CEO and CFO certifications for the financial year ended December 31, 2018 (the "Required Filings"), will be [...]
CINCINNATI, OH, April 25, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods sales & marketing and cannabis delivery development company, today announced its Notice of Allowance for U.S Application Serial Number 16/350,351 from the U.S. Patent and Trademark Office (USPTO) [...]
CINCINNATI, OH, April 19, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) announced today that it has signed a letter of intent with Simply Wholeistic to manufacture and supply formulations of CannaStrip and other Simply Wholistic dietary supplement products for retail sale in the United States. Since [...]
CINCINNATI, OH, March 12, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that Joshua Maurice has been promoted to vice president of sales and business development for Callitas, effective March 12, 2019. [...]
CINCINNATI, OH, February 26, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, announced today that it has amended and expanded its original agreement with NFI Consumer Healthcare. The new agreement includes distribution of [...]
